Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia.

Abstract

Hematide is a synthetic peptide-based erythropoiesis-stimulating agent that is being developed by Affymax Inc and Takeda Pharmaceutical Co Ltd. Hematide is undergoing phase III clinical trials for anemia.

• Authors: Iain C Macdougall
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 9 Issue 9 Pg. 1034-47 (Sep 2008) ISSN: 1472-4472 [Print] England
• PMID: 18729010 (Publication Type: Journal Article, Review)

Chemical References

• Peptides
• hematide
• Polyethylene Glycols

Topics

• Anemia (drug therapy)
• Animals
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Erythropoiesis (drug effects)
• Humans
• Patents as Topic
• Peptides (adverse effects, pharmacokinetics, pharmacology, therapeutic use, toxicity)
• Polyethylene Glycols (adverse effects, pharmacokinetics, pharmacology, therapeutic use, toxicity)
• Structure-Activity Relationship